818 reports of this reaction
1.6% of all DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS reports
#6 most reported adverse reaction
HYPOTENSION is the #6 most commonly reported adverse reaction for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, manufactured by Accord Healthcare, Inc.. There are 818 FDA adverse event reports linking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS to HYPOTENSION. This represents approximately 1.6% of all 50,803 adverse event reports for this drug.
Patients taking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS who experience hypotension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTENSION is a less commonly reported adverse event for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, but still significant enough to appear in the safety profile.
In addition to hypotension, the following adverse reactions have been reported for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS:
The following drugs have also been linked to hypotension in FDA adverse event reports:
HYPOTENSION has been reported as an adverse event in 818 FDA reports for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTENSION accounts for approximately 1.6% of all adverse event reports for DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, making it a notable side effect.
If you experience hypotension while taking DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.